Vincent Woo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Vincent Woo has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
Alan Bell
University of Toronto, Toronto, Ontario, Canada
2 shared publicationsFernando Camacho
University of Waterloo, Waterloo, Ontario, Canada
2 shared publications- Ildiko Lingvay
Department of Internal Medicine/Endocrinology UT Southwestern Medical Center Dallas Texas USA
2 shared publications Jennifer B. Rose
Janssen Inc, Toronto, Ontario, Canada
2 shared publicationsLuis Noronha
Diabetes Heart Research Center, Toronto, Ontario, Canada
2 shared publicationsMaureen Clement
University of British Columbia, Vancouver, British Columbia, Canada
2 shared publications
Latest Publications
- 1 October 2019
- Published by Elsevier in Canadian Journal of Diabetes
- Vol. 43 (7) , 464-471
CANadian CAnagliflozin REgistry: Patient-Reported Outcomes of Canagliflozin in the Treatment of Type 2 Diabetes Mellitus in Canadian Clinical Practice
- 1 October 2019
- Published by Elsevier in Canadian Journal of Diabetes
- Vol. 43 (7) , 464-471
CANadian CAnagliflozin REgistry: Patient-Reported Outcomes of Canagliflozin in the Treatment of Type 2 Diabetes Mellitus in Canadian Clinical Practice
- Top Cited PapersOpen Access
- 1 October 2019
- Published by Elsevier in Diabetes & Metabolism
- Vol. 45 (5) , 409-418
Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: Insights from the SUSTAIN 1–7 trials
- 1 October 2019
- Published by Elsevier in Diabetes & Metabolism
- Vol. 45 (5) , 409-418
Top Cited PapersOpen AccessComparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: Insights from the SUSTAIN 1–7 trials
- Open Access
- 4 November 2018
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 21 (3) , 691-699
CANadian CAnagliflozin REgistry: Effectiveness and safety of canagliflozin in the treatment of type 2 diabetes mellitus in Canadian clinical practice
Aim: There is limited information concerning the effects of canagliflozin (CANA), a sodium‐glucose co‐transporter 2 inhibitor (SGLT2i) in a real‐world clinical setting in Canada. CanCARE is a 12‐month, prospective, observational analysis to demonstrate the effectiveness and safety of CANA in usual clinical practice in Canada. Materials and methods: SGLT2i‐naïve adult patients with type 2 diabetes mellitus (T2DM) (n = 527) on a stable antihyperglycemic agent (AHA) regimen with glycated hemoglobin (A1C) ≥ 7%, an estimated glomerular filtration rate (eGFR) ≥ 60 mL/min/1.73m 2 , were initiated on CANA as part of their usual treatment approach, and were followed for a period of 12 months. The primary effectiveness objective was the mean change in HbA1c from baseline to 6 and 12 months. Results: Significant improvement from baseline in mean HbA1c levels were observed at 6 months (−0.90%; 95% CI, −1.02, −0.78) and at 12 months (−1.04%; 95% CI, −1.15, −0.92), regardless of duration of diabetes or background AHA treatment regimen. Similarly, significant decreases in systolic blood pressure (−4.65 mm Hg); body weight (−3.24 kg), waist circumference (−2.91 cm) and body mass index (−1.15 kg/m 2 ) were observed at 12 months. Additionally, 40.5% of patients achieved the double endpoint (≥0.5% HbA1c reduction and ≥ 3% weight loss), while 24.3% of patients achieved the triple composite endpoint (≥0.5% HbA1c reduction, ≥3% weight loss and ≥ 4 mm Hg systolic blood pressure reduction). No unexpected adverse events were reported. Conclusion: CANA provided sustained clinically meaningful improvements in cardiometabolic parameters in this study in a real‐world setting, confirming findings from randomized controlled trials.
- 4 November 2018
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 21 (3) , 691-699
Open AccessCANadian CAnagliflozin REgistry: Effectiveness and safety of canagliflozin in the treatment of type 2 diabetes mellitus in Canadian clinical practice
Aim: There is limited information concerning the effects of canagliflozin (CANA), a sodium‐glucose co‐transporter 2 inhibitor (SGLT2i) in a real‐world clinical setting in Canada. CanCARE is a 12‐month, prospective, observational analysis to demonstrate the effectiveness and safety of CANA in usual clinical practice in Canada. Materials and methods: SGLT2i‐naïve adult patients with type 2 diabetes mellitus (T2DM) (n = 527) on a stable antihyperglycemic agent (AHA) regimen with glycated hemoglobin (A1C) ≥ 7%, an estimated glomerular filtration rate (eGFR) ≥ 60 mL/min/1.73m 2 , were initiated on CANA as part of their usual treatment approach, and were followed for a period of 12 months. The primary effectiveness objective was the mean change in HbA1c from baseline to 6 and 12 months. Results: Significant improvement from baseline in mean HbA1c levels were observed at 6 months (−0.90%; 95% CI, −1.02, −0.78) and at 12 months (−1.04%; 95% CI, −1.15, −0.92), regardless of duration of diabetes or background AHA treatment regimen. Similarly, significant decreases in systolic blood pressure (−4.65 mm Hg); body weight (−3.24 kg), waist circumference (−2.91 cm) and body mass index (−1.15 kg/m 2 ) were observed at 12 months. Additionally, 40.5% of patients achieved the double endpoint (≥0.5% HbA1c reduction and ≥ 3% weight loss), while 24.3% of patients achieved the triple composite endpoint (≥0.5% HbA1c reduction, ≥3% weight loss and ≥ 4 mm Hg systolic blood pressure reduction). No unexpected adverse events were reported. Conclusion: CANA provided sustained clinically meaningful improvements in cardiometabolic parameters in this study in a real‐world setting, confirming findings from randomized controlled trials.
- Open Access
- 27 September 2018
- Published by Georg Thieme Verlag KG
- Vol. 11 (S 01) , Trab721
Semaglutide Provides Superior Body Weight Reduction Across Sustain 1–5 Clinical Trials
Introdução: The SUSTAIN 1–5 trials evaluated subcutaneous (s.c.) semaglutide, a GLP-1 analog, in subjects with type 2 Diabetes (T2D) vs. placebo, sitagliptin, exenatide extended-release (ER), insulin glargine and as add on to insulin. Objetivo: to characterize the effects of semaglutide treatment on body weight in subjects with T2D acress the SUSTAIN 1–5 trials, covering the T2D treatment continuum. Metodologia: In these phase 3 a trials, subjects with inadequately controlled T2D who were drug-naïve (SUSTAIN 1), on metformin and/or thiazolidinediones (SUSTAIN 2), on 1–2 oral antidiabetic drugs (SUSTAIN 3), on metformin ± sulphonylureas (SUSTAIN 4) or on basal insulin ± metformin (SUSTAIN 5) were randomised to semaglutide s.c. 0.5 mg (excluding SUSTAIN 3) or 1.0 mg (all trials) once weekly. The primary endpoint was HbA1c. Pre-specified analyses included change from baseline in body weight, proportion of subjects with ≥5% and ≥10% BW loss from baseline, change in body mass index (BMI) and waist circumference. Resultados: a mean BW loss of 3.5–6.4 kg from baseline was observed with QW Semaglutide vs. 1.9 kg reduction to 1.2 kg increase for comparators (p < 0.0001; Figure). Semaglutide treatment led to greater proportions of subjects achieving ≥5% and ≥10% BW loss vs. comparators, and significant reductions in BMI and waist circumference (p < 0.05; Table). Conclusão: Semaglutide provided clinically meaningful reductions in body weight, BMI and waist circumference vs. comparators in a broad range of subjects with T2D. The effect of semaglutide on weight was (vs all comparators): consistent across a broad range of patients with T2D. Clinically meaningful, with many patients achieving ≥5% and ≥10%.
- 27 September 2018
- Published by Georg Thieme Verlag KG
- Vol. 11 (S 01) , Trab721
Open AccessSemaglutide Provides Superior Body Weight Reduction Across Sustain 1–5 Clinical Trials
Introdução: The SUSTAIN 1–5 trials evaluated subcutaneous (s.c.) semaglutide, a GLP-1 analog, in subjects with type 2 Diabetes (T2D) vs. placebo, sitagliptin, exenatide extended-release (ER), insulin glargine and as add on to insulin. Objetivo: to characterize the effects of semaglutide treatment on body weight in subjects with T2D acress the SUSTAIN 1–5 trials, covering the T2D treatment continuum. Metodologia: In these phase 3 a trials, subjects with inadequately controlled T2D who were drug-naïve (SUSTAIN 1), on metformin and/or thiazolidinediones (SUSTAIN 2), on 1–2 oral antidiabetic drugs (SUSTAIN 3), on metformin ± sulphonylureas (SUSTAIN 4) or on basal insulin ± metformin (SUSTAIN 5) were randomised to semaglutide s.c. 0.5 mg (excluding SUSTAIN 3) or 1.0 mg (all trials) once weekly. The primary endpoint was HbA1c. Pre-specified analyses included change from baseline in body weight, proportion of subjects with ≥5% and ≥10% BW loss from baseline, change in body mass index (BMI) and waist circumference. Resultados: a mean BW loss of 3.5–6.4 kg from baseline was observed with QW Semaglutide vs. 1.9 kg reduction to 1.2 kg increase for comparators (p < 0.0001; Figure). Semaglutide treatment led to greater proportions of subjects achieving ≥5% and ≥10% BW loss vs. comparators, and significant reductions in BMI and waist circumference (p < 0.05; Table). Conclusão: Semaglutide provided clinically meaningful reductions in body weight, BMI and waist circumference vs. comparators in a broad range of subjects with T2D. The effect of semaglutide on weight was (vs all comparators): consistent across a broad range of patients with T2D. Clinically meaningful, with many patients achieving ≥5% and ≥10%.
- 1 April 2016
- Published by Elsevier in Canadian Journal of Diabetes
- Vol. 40 (2) , 149-151
A Study of Diabetes Teaching in Canadian Medical Schools
- 1 April 2016
- Published by Elsevier in Canadian Journal of Diabetes
- Vol. 40 (2) , 149-151
A Study of Diabetes Teaching in Canadian Medical Schools
- Open Access
- 25 August 2015
- Published by Wiley in International Journal Of Clinical Practice
- Vol. 69 (12) , 1427-1437
Empagliflozin/linagliptin single‐tablet combination: first‐in‐class treatment option
The availability of a dual sodium glucose co-transporter 2/dipeptidyl peptidase-4 inhibitor combination in a single-tablet combination (STC) represents a new therapeutic option for patients with type 2 diabetes. Empagliflozin/linagliptin STC has been recently approved by the US Food and Drug Administration for the treatment of type 2 diabetes mellitus (T2DM). The aim of this study was to describe the latest clinical evidence on the efficacy and safety profiles of empagliflozin/linagliptin STCs in comparison with the individual components. Juxtaposition of the STC with dapagliflozin/saxagliptin combination was also presented. Empagliflozin/linagliptin STC given as initial therapy or on metformin background lowered mean glycated haemoglobin (HbA1c) by approximately 1.1% (mean baseline HbA1c, 8.0%). Furthermore, the STC reduced mean body weight by 2.0-3.0 kg from baseline. With the STC treatment, no confirmed incidents of hypoglycaemia were reported in drug-naïve patients; in patients taking metformin hypoglycaemia occurred at low rates which were comparable with monotherapy. Use of STCs in the treatment of T2DM can simplify drug dosing regimen, reduce pill burden and increase treatment adherence. Empagliflozin/linagliptin STC is a combination that offers potential additional benefits such as body weight loss and moderate reductions in blood pressure, without increasing risk of hypoglycaemia. Empagliflozin/linagliptin STC appears to be a rational choice for a wide range of patients in need of multiple agents for controlling hyperglycaemia. The STC should be particularly useful in patients in whom hypoglycaemia, weight gain and treatment adherence are of concern.
- 25 August 2015
- Published by Wiley in International Journal Of Clinical Practice
- Vol. 69 (12) , 1427-1437
Open AccessEmpagliflozin/linagliptin single‐tablet combination: first‐in‐class treatment option
The availability of a dual sodium glucose co-transporter 2/dipeptidyl peptidase-4 inhibitor combination in a single-tablet combination (STC) represents a new therapeutic option for patients with type 2 diabetes. Empagliflozin/linagliptin STC has been recently approved by the US Food and Drug Administration for the treatment of type 2 diabetes mellitus (T2DM). The aim of this study was to describe the latest clinical evidence on the efficacy and safety profiles of empagliflozin/linagliptin STCs in comparison with the individual components. Juxtaposition of the STC with dapagliflozin/saxagliptin combination was also presented. Empagliflozin/linagliptin STC given as initial therapy or on metformin background lowered mean glycated haemoglobin (HbA1c) by approximately 1.1% (mean baseline HbA1c, 8.0%). Furthermore, the STC reduced mean body weight by 2.0-3.0 kg from baseline. With the STC treatment, no confirmed incidents of hypoglycaemia were reported in drug-naïve patients; in patients taking metformin hypoglycaemia occurred at low rates which were comparable with monotherapy. Use of STCs in the treatment of T2DM can simplify drug dosing regimen, reduce pill burden and increase treatment adherence. Empagliflozin/linagliptin STC is a combination that offers potential additional benefits such as body weight loss and moderate reductions in blood pressure, without increasing risk of hypoglycaemia. Empagliflozin/linagliptin STC appears to be a rational choice for a wide range of patients in need of multiple agents for controlling hyperglycaemia. The STC should be particularly useful in patients in whom hypoglycaemia, weight gain and treatment adherence are of concern.
- 25 June 2014
- Published by Taylor & Francis in Expert Review of Endocrinology & Metabolism
- Vol. 9 (5) , 435-443
Dapagliflozin for the treatment of Type 2 diabetes
Dapagliflozin is a sodium glucose co-transporter 2 inhibitor that causes glucose to be lost in the urine. This mechanism of action lowers glucose levels throughout the day and is associated with significant weight loss and moderate blood pressure lowering without increasing heart rate. This class of medications are well tolerated but have a higher incidence of genital tract fungal infections and a slight increase in urinary tract infections that are usually easily treated and not recurrent. Dapagliflozin represents a new medication that should help many individuals with Type 2 diabetes achieve their therapeutic targets.
- 25 June 2014
- Published by Taylor & Francis in Expert Review of Endocrinology & Metabolism
- Vol. 9 (5) , 435-443
Dapagliflozin for the treatment of Type 2 diabetes
Dapagliflozin is a sodium glucose co-transporter 2 inhibitor that causes glucose to be lost in the urine. This mechanism of action lowers glucose levels throughout the day and is associated with significant weight loss and moderate blood pressure lowering without increasing heart rate. This class of medications are well tolerated but have a higher incidence of genital tract fungal infections and a slight increase in urinary tract infections that are usually easily treated and not recurrent. Dapagliflozin represents a new medication that should help many individuals with Type 2 diabetes achieve their therapeutic targets.
- 11 November 2008
- Published by Hindawi Limited in International Journal Of Clinical Practice
- Vol. 62 (12) , 1935-1942
Targets and tactics: the relative importance of HbA1c, fasting and postprandial plasma glucose levels to glycaemic control in type 2 diabetes
Background: The incidence of type 2 diabetes is reaching pandemic proportions, impacting patients and healthcare systems across the globe. Evidence suggests that a majority of patients are not achieving recommended blood glucose targets resulting in an increased risk of micro‐ and macro‐vascular complications. Aim: To review literature on the significance of glycosylated haemoglobin (HbA1c), fasting plasma glucose (FPG) and postprandial plasma glucose (PPG), their inter‐relationships and relative importance in the treatment of diabetes, and to provide practical guidance on effective monitoring of patients. Methods: Clinical guidelines on diabetes management and clinical and preclinical studies of glycaemic control identified through a publications database search were reviewed. Results: Glycaemic control remains fundamental to the successful management of diabetes. HbA1c is the gold standard measure of glycaemic control but recent evidence suggests that postmeal hyperglycaemia also plays an important role in the aetiology of diabetes‐associated complications and control of PPG levels is vital to the achievement of recommended HbA1c targets. Conclusions: The call for action on type 2 diabetes has never been more compelling; with a clear focus on strategies for glycaemic control, the impact of the diabetes pandemic can be limited.
- 11 November 2008
- Published by Hindawi Limited in International Journal Of Clinical Practice
- Vol. 62 (12) , 1935-1942
Targets and tactics: the relative importance of HbA1c, fasting and postprandial plasma glucose levels to glycaemic control in type 2 diabetes
Background: The incidence of type 2 diabetes is reaching pandemic proportions, impacting patients and healthcare systems across the globe. Evidence suggests that a majority of patients are not achieving recommended blood glucose targets resulting in an increased risk of micro‐ and macro‐vascular complications. Aim: To review literature on the significance of glycosylated haemoglobin (HbA1c), fasting plasma glucose (FPG) and postprandial plasma glucose (PPG), their inter‐relationships and relative importance in the treatment of diabetes, and to provide practical guidance on effective monitoring of patients. Methods: Clinical guidelines on diabetes management and clinical and preclinical studies of glycaemic control identified through a publications database search were reviewed. Results: Glycaemic control remains fundamental to the successful management of diabetes. HbA1c is the gold standard measure of glycaemic control but recent evidence suggests that postmeal hyperglycaemia also plays an important role in the aetiology of diabetes‐associated complications and control of PPG levels is vital to the achievement of recommended HbA1c targets. Conclusions: The call for action on type 2 diabetes has never been more compelling; with a clear focus on strategies for glycaemic control, the impact of the diabetes pandemic can be limited.